Trial Outcomes & Findings for DePuy Trochanteric (ATN) Nailing Clinical Outcomes Trial (NCT NCT00546429)

NCT ID: NCT00546429

Last Updated: 2023-06-06

Results Overview

Merle D'Aubigne measures three categories for Pain, Mobility and Ability to walk using a 0 to 6 scoring scale for each category. Scoring is 0 indicating worse outcomes and 6 indicating better outcomes. Each Category is scored and reported separately

Recruitment status

COMPLETED

Target enrollment

62 participants

Primary outcome timeframe

4 weeks, 3, 6 and 12 months

Results posted on

2023-06-06

Participant Flow

Between September 2006 \& September 2009, 62 subjects were recruited and enrolled at 6 US clinics by orthopaedic surgeons. Each study site could enroll up to 20 subjects (cohorts were re-assigned as necessary to complete enrollment in a timely manner). Recruitment was based on the inclusion and exclusion criteria in the clinical investigation plan.

This was a non-randomized study so all subjects that met the inclusion/exclusion criteria received the ATN Trochanteric Nail. Consented subjects could be excluded from the trial based on results of pre-operative clinical and/or radiographic evaluations, as per the exclusion criteria in the clinical investigation plan.

Participant milestones

Participant milestones
Measure
DePuy Orthopaedics ATN Trochanteric Nail System
The participants in this study will undergo treatment of trochanteric fractures using DePuy Orthopaedics ATN Trochanteric Nail System implants and results will be reviewed by clinical and radiographic evaluations.
Overall Study
STARTED
62
Overall Study
COMPLETED
32
Overall Study
NOT COMPLETED
30

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

DePuy Trochanteric (ATN) Nailing Clinical Outcomes Trial

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
DePuy Orthopaedics ATN Trochanteric Nail System
n=62 Participants
The participants in this study will undergo treatment of trochanteric fractures using DePuy Orthopaedics ATN Trochanteric Nail System implants and results will be reviewed by clinical and radiographic evaluations.
Age, Continuous
79.2 years
STANDARD_DEVIATION 14.1 • n=5 Participants
Sex: Female, Male
Female
42 Participants
n=5 Participants
Sex: Female, Male
Male
20 Participants
n=5 Participants
Region of Enrollment
United States · United States
62 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 4 weeks, 3, 6 and 12 months

Merle D'Aubigne measures three categories for Pain, Mobility and Ability to walk using a 0 to 6 scoring scale for each category. Scoring is 0 indicating worse outcomes and 6 indicating better outcomes. Each Category is scored and reported separately

Outcome measures

Outcome measures
Measure
DePuy Orthopaedics ATN Trochanteric Nail System
n=60 Participants
The participants in this study will undergo treatment of trochanteric fractures using DePuy Orthopaedics ATN Trochanteric Nail System implants and results will be reviewed by clinical and radiographic evaluations.
Success in Terms of the Merle D'Aubigne Postel Score for Pain Category
4 Week Merle D'Aubigne for Pain Score (0 worst to 6 best)
4.1 Units on a scale
Standard Deviation 1.2
Success in Terms of the Merle D'Aubigne Postel Score for Pain Category
3 Month Merle D'Aubigne Pain Score (0 worst to 6 best)
4.4 Units on a scale
Standard Deviation 1.4
Success in Terms of the Merle D'Aubigne Postel Score for Pain Category
6 Month Merle D'Aubigne Pain Score (0 worst to 6 best)
4.5 Units on a scale
Standard Deviation 1.3
Success in Terms of the Merle D'Aubigne Postel Score for Pain Category
12 Month Merle D'Aubigne Pain Score (0 worst to 6 best)
4.6 Units on a scale
Standard Deviation 1.6

PRIMARY outcome

Timeframe: 4 weeks, 3, 6 and 12 months

Merle D'Aubigne measures three categories for Pain, Mobility and Ability to walk using a 0 to 6 scoring scale for each category. Scoring is 0 indicating worse outcomes and 6 indicating better outcomes. Each Category is scored and reported separately

Outcome measures

Outcome measures
Measure
DePuy Orthopaedics ATN Trochanteric Nail System
n=60 Participants
The participants in this study will undergo treatment of trochanteric fractures using DePuy Orthopaedics ATN Trochanteric Nail System implants and results will be reviewed by clinical and radiographic evaluations.
Success in Terms of the Merle D'Aubigne Postel Score for Walk Category
4 Week Merle D'Aubigne for Walk Score (0 worst to 6 best)
1.3 Units on a scale
Standard Deviation 1.3
Success in Terms of the Merle D'Aubigne Postel Score for Walk Category
3 Month Merle D'Aubigne Walk Score (0 worst to 6 best)
2.6 Units on a scale
Standard Deviation 1.7
Success in Terms of the Merle D'Aubigne Postel Score for Walk Category
6 Month Merle D'Aubigne Walk Score (0 worst to 6 best)
3.0 Units on a scale
Standard Deviation 1.9
Success in Terms of the Merle D'Aubigne Postel Score for Walk Category
12 Month Merle D'Aubigne Walk Score (0 worst to 6 best)
2.7 Units on a scale
Standard Deviation 1.9

PRIMARY outcome

Timeframe: 4 weeks, 3, 6 and 12 months

Merle D'Aubigne measures three categories for Pain, Mobility and Ability to walk using a 0 to 6 scoring scale for each category. Scoring is 0 indicating worse outcomes and 6 indicating better outcomes. Each Category is scored and reported separately

Outcome measures

Outcome measures
Measure
DePuy Orthopaedics ATN Trochanteric Nail System
n=60 Participants
The participants in this study will undergo treatment of trochanteric fractures using DePuy Orthopaedics ATN Trochanteric Nail System implants and results will be reviewed by clinical and radiographic evaluations.
Success in Terms of the Merle D'Aubigne Postel Score for Mobility Category
4 Week Merle D'Aubigne for Mobility Score (0 worst to 6 best)
5.2 Units on a scale
Standard Deviation 1.3
Success in Terms of the Merle D'Aubigne Postel Score for Mobility Category
3 Month Merle D'Aubigne Mobility Score (0 worst to 6 best)
5.4 Units on a scale
Standard Deviation 1.0
Success in Terms of the Merle D'Aubigne Postel Score for Mobility Category
6 Month Merle D'Aubigne Mobility Score (0 worst to 6 best)
5.4 Units on a scale
Standard Deviation 1.0
Success in Terms of the Merle D'Aubigne Postel Score for Mobility Category
12 Month Merle D'Aubigne Mobility Score (0 worst to 6 best)
5.6 Units on a scale
Standard Deviation 0.8

SECONDARY outcome

Timeframe: 4 weeks, 3, 6 and 12 months

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 4 weeks, 3, 6 and 12 months

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 4 weeks, 3, 6 and 12 months

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 4 weeks, 3, 6 and 12 months

Outcome measures

Outcome data not reported

Adverse Events

DePuy Orthopaedics ATN Trochanteric Nail System

Serious events: 3 serious events
Other events: 4 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
DePuy Orthopaedics ATN Trochanteric Nail System
n=62 participants at risk
The participants in this study will undergo treatment of trochanteric fractures using DePuy Orthopaedics ATN Trochanteric Nail System implants and results will be reviewed by clinical and radiographic evaluations.
Musculoskeletal and connective tissue disorders
Bone fracture acetabulum
1.6%
1/62 • Number of events 1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer
1.6%
1/62 • Number of events 1
General disorders
Death
1.6%
1/62 • Number of events 1
Injury, poisoning and procedural complications
Implant removal
1.6%
1/62 • Number of events 1

Other adverse events

Other adverse events
Measure
DePuy Orthopaedics ATN Trochanteric Nail System
n=62 participants at risk
The participants in this study will undergo treatment of trochanteric fractures using DePuy Orthopaedics ATN Trochanteric Nail System implants and results will be reviewed by clinical and radiographic evaluations.
Respiratory, thoracic and mediastinal disorders
Respiratory system
6.5%
4/62 • Number of events 4

Additional Information

Sam Himden

DePuy Orthopaedics, Inc.

Phone: 574-372-7231

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60